Key result
Hypertension is the most common comorbidity in fatal COVID-19, present in ~46% of cases.
Meta-Analysis
INTRODUCTION: Underlying disease have a critical role in vulnerability of populations for a greater morbidity and mortality when they suffer from COVID-19. The aim of current study is evaluating the prevalence of underlying disease in died people with COVID-19. METHODS: The current study have been conducted according to PRISMA guideline. International database including PubMed, Scopus, Web of Science, Cochrane and google scholar were searched for relevant studies up to 1 June. All relevant articles that reported underlying disease in died cases of COVID-19 were included in the analysis. RESULTS: After screening and excluding duplicated and irrelevant studies, 32 articles included in the analysis. The most prevalent comorbidities were hypertension, diabetes, cardiovascular disease, liver disease, lung disease, malignancy, cerebrovascular disease, COPD and asthma. Among all reported underlying disease, highest and lowest prevalence was related to hypertension and asthma which were estimated 46% (37% - 55%) and 3% (2%- 6%), respectively. CONCLUSION: In summary, underlying disease have a critical role in poor outcomes, severity of disease and high mortality rate of COVID-19 cases. Patients with hypertension, cardiovascular disease and diabetes should be carefully monitored and be aware of health protocols.
No takes yet. Share an insight, caveat, or question.
Javanmardi et al. (2020) conducted a meta-analysis in COVID-19. Underlying diseases (comorbidities) was evaluated on Prevalence of underlying diseases (95% CI 37-55). In a meta-analysis of 32 articles, hypertension was the most prevalent underlying disease among fatal COVID-19 cases, with an estimated prevalence of 46% (CI 37%-55%).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: